|
Characterization and Evaluation of combination of Aromatase Inhibitor Resveratrol and Docetaxel against ER positive cell lines MCF-7 and ER negative cell lines MDAMB231 in Breast Cancer
|
|
| Author:
|
PREETI SINGH, SHIV KR YADAV, SATISH SARDANA, UROOJ A. KHAN, RUPA GUPTA
|
| Abstract:
|
In the etiology of breast cancer, estrogens have been used and added to the list of known human carcinogens. Estrogens caused breast cancer and stimulate cell growth and cause proliferation via receptor mediated processes and the genotoxic metabolites. In the current work Resveratrol was extracted and isolated from grape seeds (Vitis vinifera), percent yield of Resveratrol was found 1.0% of crude extract and extract was standardized through TLC and UV-visible spectrophotometry. Drug-Drug interaction studies were done with the help of FT-IR before testing them on breast cancer cell lines. Here, we are combining aromatase inhibitor Resveratrol with anti-cancer drug Docetaxel to observe the synergistic/preventive/therapeutic potential of combination against ER positive cell lines MCF-7 and ER negative cell lines MDAMB231. Characterization of Resveratrol and Docetaxel has been done through UV method, FTIR and HPLC. The cell viability has been tested with the help of MTT Bioassay. The current study describes in detail the critical link between inflammation and cancer. Optimization of the doses for anticancer combination has been done with the help of MTT bioassay (ED50, ED75, ED90, and ED95).
|
| Keyword:
|
Aromatase Inhibitor, Breast Cancer, Cell lines, Docetaxel, MTT Bioassay, Resveratrol.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.01.646
|
| Download:
|
Request For Article
|
|
|